Page last updated: 2024-12-07

sch 39370

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sch 39370: RN given refers to (D)-hydroxy-isomer; RN for cpd without isomeric designation not available 9/89; structure given in first source; inhibits neutral metalloendopeptidase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID121872
SCHEMBL ID5924886
MeSH IDM0168378

Synonyms (10)

Synonym
n-(n-(1-carboxyl-3-phenylpropyl)phenylalanyl)isoserine
n-(n-(1-carboxyl-3-phenylpropyl)-phe)-iso-ser
sch 39370
sch-39370
beta-alanine, n-(n-(1-carboxy-3-phenylpropyl)-l-phenylalanyl)-2-hydroxy-, (s-(r*,r*))-
115406-23-0
SCHEMBL5924886
DTXSID10921732
2-({1-[(2-carboxy-2-hydroxyethyl)imino]-1-hydroxy-3-phenylpropan-2-yl}amino)-4-phenylbutanoic acid
2-[[(2s)-1-[(2-carboxy-2-hydroxyethyl)amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-phenylbutanoic acid

Research Excerpts

Actions

ExcerptReferenceRelevance
"SCH 39370 tended to increase AUC, but the changes were not significant."( Influence of C-ANF receptor and neutral endopeptidase on pharmacokinetics of ANF in rats.
Chiu, PJ; Foster, CJ; Romano, MT; Sybertz, EJ; Tetzloff, G, 1991
)
1

Treatment

ExcerptReferenceRelevance
"SCH 39370 treatment resulted in an initial increase in urine volume in rats with CHF whereas urine sodium excretion did not change significantly."( Elevation of plasma atrial natriuretic peptide in rats with chronic heart failure by SCH 39370, a neutral metalloendopeptidase inhibitor.
Fyhrquist, F; Helin, K; Näveri, H; Sariola, H; Sybertz, EJ; Tikkanen, I; Tikkanen, T; Vemulapalli, S, 1990
)
1.22

Pharmacokinetics

ExcerptReferenceRelevance
" After a bolus injection of 125I-ANF, the resulting area under the plasma concentration curve (AUC) with C-ANF treatment was seven times the control value with regard to trichloroacetic acid-precipitable (TCA-ppt) radioactivity (intact ANF)."( Influence of C-ANF receptor and neutral endopeptidase on pharmacokinetics of ANF in rats.
Chiu, PJ; Foster, CJ; Romano, MT; Sybertz, EJ; Tetzloff, G, 1991
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (4.00)18.7374
1990's20 (80.00)18.2507
2000's4 (16.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.70 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index6.00 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.00%)5.53%
Reviews1 (4.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (92.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]